What is HC Wainwright's Forecast for AUTL FY2027 Earnings?

Key Points

• HC Wainwright raised its FY2027 EPS forecast for Autolus Therapeutics to a loss of $0.69 per share from a projected loss of $0.74, and maintained a “Buy” rating.
• For subsequent years, HC Wainwright estimates losses of $0.81 per share in FY2028, $0.69 in FY2029, and $0.22 in FY2030.
• Autolus reported quarterly EPS of a $0.21 loss, matching consensus, while revenue of $41.24 million exceeded the $39.54 million estimate.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Equities researchers at HC Wainwright raised their FY2027 earnings per share estimates for Autolus Therapeutics in a report released on Wednesday, November 11th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.69) for the year, up from their prior estimate of ($0.74). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Autolus Therapeutics' current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Autolus Therapeutics' FY2028 earnings at ($0.81) EPS, FY2029 earnings at ($0.69) EPS and FY2030 earnings at ($0.22) EPS.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The company had revenue of $41.24 million for the quarter, compared to the consensus estimate of $39.54 million. Autolus Therapeutics had a negative return on equity of 263.25% and a negative net margin of 186.37%. During the same quarter in the prior year, the business earned ($0.30) EPS.

A number of other analysts have also weighed in on the stock. Wall Street Zen upgraded shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, August 16th. UBS Group reiterated a "buy" rating on shares of Autolus Therapeutics in a research note on Wednesday. Finally, Weiss Ratings downgraded shares of Autolus Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Autolus Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $10.00.

Autolus Therapeutics Stock Performance

Shares of AUTL opened at $1.19 on Friday. Autolus Therapeutics has a 1 year low of $1.12 and a 1 year high of $2.58. The stock has a market capitalization of $316.94 million, a PE ratio of -1.23 and a beta of 2.32. The company has a debt-to-equity ratio of 5.25, a quick ratio of 4.40 and a current ratio of 3.72. The stock has a 50-day simple moving average of $1.72 and a 200-day simple moving average of $1.66.

Institutional Trading of Autolus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Syncona Portfolio Ltd purchased a new stake in Autolus Therapeutics during the 2nd quarter worth about $26,625,152. Alphabet Inc. acquired a new position in shares of Autolus Therapeutics during the 2nd quarter worth about $1,117,000. Cetera Investment Advisers increased its holdings in shares of Autolus Therapeutics by 2.7% in the 1st quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company's stock valued at $1,558,000 after acquiring an additional 29,324 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Autolus Therapeutics by 2.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company's stock valued at $722,000 after acquiring an additional 11,197 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Autolus Therapeutics by 115.6% in the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company's stock valued at $25,000 after acquiring an additional 8,309 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing engineered T-cell therapies for cancer. Its treatments are designed to program a patient's T cells to recognize and attack specific cancer cells, using the company's proprietary cell-engineering technology. The company's lead therapy, obecabtagene autoleucel (obe-cel), is marketed as Aucel and is approved in the United States and European Union for certain adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.